Cardiac disease in pregnancy medical therapy

Cardiac disease in pregnancy Microchapters
Home
Overview
Pathophysiology
Epidemiology and Demographics
Risk Factors
Diagnosis
History and Symptoms
Physical Examination
Electrocardiogram
Exercise Testing
Radiation Exposure
Chest X Ray
Echocardiography
MRI
CT
Catheterization: Pulmonary artery catheterization Cardiac catheterization Cardiac Ablation
Treatment
Cardiovascular Drugs in Pregnancy
Labor and delivery
Resuscitation in Late Pregnancy
Contraindications to pregnancy
Special Scenarios: I. Pre-existing Cardiac Disease: Congenital Heart Disease Repaired Congenital Heart Disease Pulmonary Hypertension Rheumatic Heart Disease Connective Tissue Disorders II. Valvular Heart Disease: Mitral Stenosis Mitral Regurgitation Aortic Insufficiency Aortic Stenosis Mechanical Prosthetic Valves Tissue Prosthetic Valves III. Cardiomyopathy: Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Peripartum Cardiomyopathy IV. Cardiac diseases that may develop During Pregnancy: Arrhythmias Acute Myocardial Infarction Hypertension
Cardiac disease in pregnancy medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac disease in pregnancy medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac disease in pregnancy medical therapy
CDC on Cardiac disease in pregnancy medical therapy
Cardiac disease in pregnancy medical therapy in the news
Blogs on Cardiac disease in pregnancy medical therapy
Directions to Hospitals Treating Cardiac disease in pregnancy
Risk calculators and risk factors for Cardiac disease in pregnancy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Antibiotic Prophylaxis

The official American Heart Association (AHA) recommendation is that antibody prophylaxis is not necessary for an uncomplicated delivery except among patients with a prosthetic heart valve or surgically constructed systemic to pulmonary shunt. However, because of the difficulties in predicting complicated deliveries and the potential devastating consequences of endocarditis, antibiotic prophylaxis for vaginal delivery in all patients with congenital heart disease expect those with an isolated secundum type atrial septal defect and those six months or more after repair of septal defects or surgical ligation division of a patent duct is arteriosus, seems reasonable. At the time of delivery it is recommended that all women with valvular heart disease receive antibiotics, usually penicillin and gentamycin. For those with a pencillin allergy, vancomycin is used.

References

Template:WikiDoc Sources